Shrinking profits in the U.S. and increasing Chinese raw material costs threaten to disrupt Indian pharma’s strides.
Pharmacy
The country’s much smaller rivals gear up to give the global giants a run for their money.
Shrinking profits in the U.S. and increasing Chinese raw material costs threaten to disrupt Indian pharma’s strides.
The country’s much smaller rivals gear up to give the global giants a run for their money.